10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
Posts Tagged ‘NASDAQ:NBIX’
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript October 30, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript August 1, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0.4189 EPS, expectations were $1.04. Neurocrine Biosciences, Inc.
Insiders Are Dumping These 5 Healthcare Stocks
This article presents an overview of Insiders Are Dumping These 10 Healthcare Stocks. For a detailed overview of such stocks, read our article, Insiders Are Dumping These 10...
5 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the five best small-cap growth stocks to invest in.
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all participants are in a listen-only mode.
Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates
In this article, we will take a look at the 15 stocks with at least 30% annual growth rates to consider for a growth stock portfolio.
5 High Growth NASDAQ Stocks That Are Profitable
This article presents an overview of the 5 High Growth NASDAQ Stocks That Are Profitable. For a detailed overview of such stocks, read our article, 14 High Growth NASDAQ ...
5 High Growth Non-Tech Stocks That Are Profitable
This article presents an overview of the 5 High Growth Non-Tech Stocks That Are Profitable. For a detailed overview of such stocks, read our article, 17 High Growth Non-Tech...
13 High Growth Healthcare Stocks to Buy
In this article, we will take a look at 13 high growth healthcare stocks to buy.
Here’s Why Neurocrine Biosciences (NBIX) Rose in Q3
Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” third-quarter 2023 investor letter.
12 Best Low Beta Stocks To Buy
In this piece, we will take a look at the 12 best low beta stocks to buy.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript
Operator: Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results. At this time, all participants are in a listen-only mode.
14 Best Low Risk High Growth Stocks to Buy Now
In this article, we will take a look at the 14 best low risk high growth stocks to buy now.
15 Worst Performing Healthcare Stocks in 2023
In this article, we discuss 15 worst performing healthcare stocks in 2023.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Second Quarter Results.
Neurocrine Biosciences (NBIX) Failed to Impress the Market in Q1
Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” first-quarter 2023 investor letter.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Neurocrine Biosciences Reports First Quarter Results. At this time, all participants are in a listen-only mode.
5 High Growth Healthcare Stocks to Buy
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is one of the high growth healthcare companies that is working on treatments for neuropsychiatric and neurologic disorders.
Analysts Are Revising Price Targets of These 10 Stocks Post Earnings
In this article, we will discuss the 10 stocks that recently received updated price targets from analysts post earnings.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year End Results.
15 Biggest Neuroscience Companies in the World
In this article, we will discuss the 15 Biggest Neuroscience Companies in the World.
10 Best Healthcare Stocks For Recession
The healthcare sector in 2022 outperformed the market despite several headwinds and a negative macroeconomic backdrop.
5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital
In this article, we will take a look at some important pharma stock picks of Steven Boyd's Armistice Capital.
Harding Loevner’s Biggest Contributor: Neurocrine Biosciences (NBIX)
Harding Loevner, an asset management company, released its “Global Small Companies Equity” second quarter investor letter. A copy of the same can be downloaded here.
Is it a Great Move to Buy Neurocrine Biosciences (NBIX) Shares?
ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” first quarter 2022 investor letter – a copy of which can be downloaded here...
Were Hedge Funds Right About Neurocrine Biosciences, Inc. (NBIX)?
Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.
5 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital
In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Neurocrine Biosciences, Inc. (NBIX) Fell Out Of Favor With Hedge Funds
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
15 Best Stocks to Buy for 2022 According to Analysts
In this article, we discuss the 15 best stocks to buy for 2022 according to analysts.
Hedge Funds Are Coming Back To Neurocrine Biosciences, Inc. (NBIX)
Is Neurocrine Biosciences, Inc.
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC.
Is NBIX Stock A Buy or Sell?
In this article you are going to find out whether hedge funds think Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a good investment right now.
Is NBIX A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here.
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market...
Neurocrine Biosciences (NBIX): Hedge Funds In Wait-and-See Mode
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy...
Should You Avoid Neurocrine Biosciences, Inc. (NBIX)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We...
Hedge Funds Aren’t Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Coronavirus is probably the #1 concern in investors’ minds right now. It should be.
How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd.
Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)?
A whopping number of 13F filings filed with U.S.
Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons.
